Clinical Nurse Specialist Program year 2023 Source: CMS Open Payments, 2026 publication

Katie Johnson

Clinical Nurse Specialist, Adult Health Longview, WA Clinical Nurse Specialist

NPI 1184192189 CMS profile 10586047

1615 Delaware St, Longview, WA 98632

Open in the dashboard

General payments

$139

1 record reported · program year 2023

Research payments

$0

Paid to them · None reported · program year 2023

Ownership & investment interest

$0

None reported

Through program year 2023, Katie Johnson of Longview, WA is reported in the CMS Open Payments database as having received $139 across 1 general payment and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 34th percentile of Clinical Nurse Specialist, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2023 General $139 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katie Johnson
  • Clinical Nurse Specialist, Adult Health median
  • Middle half of Clinical Nurse Specialist, Adult Health
  • National median

In program year 2025, general payments to Katie Johnson were reported at $0. Among 446 Clinical Nurse Specialist, Adult Health profiles paid that year, the median was $193 and the middle half received between $61 and $597.

Show as a table
Year Katie Johnson Clinical Nurse Specialist, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $133 $48–$445 $132
2022 $0 $163 $57–$526 $149
2023 $139 $173 $64–$597 $160
2024 $0 $171 $54–$575 $164
2025 $0 $193 $61–$597 $169

Breakdown

Who paid General payments · program year 2023
  1. Tonix Pharmaceuticals, Inc. $139 1 payment

Every payment, record by record

What the payments were for General payments · program year 2023
  1. Food and Beverage $139 1 payment
Products named General payments · program year 2023
  1. ZEMBRACE SYMTOUCH $139 1 payment
  2. TOSYMRA $139 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

970

Median for Nurse Practitioner: 389

Drug cost

$297,513

Median for Nurse Practitioner: $21,885

Branded share of claims

50%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 61 $88,232
Emgality Pen Galcanezumab-Gnlm Brand 59 $63,477
Ubrelvy Ubrogepant Brand 40 $44,939
Aimovig Autoinjector Erenumab-Aooe Brand 41 $30,414
Qulipta Atogepant Brand 18 $20,978
Ajovy Autoinjector Fremanezumab-Vfrm Brand 18 $13,128
Reyvow Lasmiditan Succinate Brand 15 $7,832
Keppra Levetiracetam Brand 12 $7,153
Depakote Sprinkle Divalproex Sodium Brand 11 $6,200
Rivastigmine Generic 12 $2,837

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$12,329

Medicare's payments for the services billed

Medicare patients

69

Average age 69

Services billed

223

51 women, 18 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 54%
Arthritis 54%
Depression 43%
Alzheimer's or dementia 28%
Chronic kidney disease 26%
Diabetes 17%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Adult Health in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record